SG11201501483XA - Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine - Google Patents

Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine

Info

Publication number
SG11201501483XA
SG11201501483XA SG11201501483XA SG11201501483XA SG11201501483XA SG 11201501483X A SG11201501483X A SG 11201501483XA SG 11201501483X A SG11201501483X A SG 11201501483XA SG 11201501483X A SG11201501483X A SG 11201501483XA SG 11201501483X A SG11201501483X A SG 11201501483XA
Authority
SG
Singapore
Prior art keywords
gemicitabine
treatment
methods
drug delivery
delivery systems
Prior art date
Application number
SG11201501483XA
Inventor
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of SG11201501483XA publication Critical patent/SG11201501483XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/04—General characteristics of the apparatus implanted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/16—Male reproductive, genital organs
    • A61M2210/166—Prostate
SG11201501483XA 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine SG11201501483XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696029P 2012-08-31 2012-08-31
PCT/US2013/057841 WO2014036556A2 (en) 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of prostate

Publications (1)

Publication Number Publication Date
SG11201501483XA true SG11201501483XA (en) 2015-03-30

Family

ID=49162284

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501483XA SG11201501483XA (en) 2012-08-31 2013-09-03 Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine

Country Status (14)

Country Link
US (2) US9636488B2 (en)
EP (1) EP2890386A2 (en)
JP (1) JP6309009B2 (en)
KR (2) KR102383496B1 (en)
CN (2) CN112516154A (en)
AU (1) AU2013308465B2 (en)
BR (1) BR112015004110A2 (en)
CA (1) CA2882575C (en)
IL (1) IL237300B (en)
IN (1) IN2015DN01560A (en)
MX (1) MX367070B (en)
RU (1) RU2678308C2 (en)
SG (1) SG11201501483XA (en)
WO (1) WO2014036556A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
SI2890384T1 (en) 2012-08-31 2022-02-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
CN113413393A (en) 2013-08-19 2021-09-21 塔里斯生物医药公司 Multi-unit drug delivery device and method
MX2016011333A (en) * 2014-03-06 2016-12-07 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
US10675289B2 (en) * 2014-10-02 2020-06-09 University Of Maryland, Baltimore Methods of treating pancreatic cancer
WO2017193098A1 (en) 2016-05-06 2017-11-09 Taris Biomedical Llc Method of treating lower tract urothelial cancer
BR112020000832A2 (en) * 2017-07-25 2020-07-21 Taris Biomedical Llc methods to treat tumor metastasis
CN111787926A (en) 2017-11-08 2020-10-16 塔里斯生物医药公司 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
CA3107461A1 (en) 2018-08-01 2020-02-06 Taris Biomedical Llc Methods of treating overactive bladder using trospium
WO2020168244A1 (en) 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
US20040260272A1 (en) 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
US8361490B2 (en) * 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DE102005020314A1 (en) * 2005-05-02 2006-11-09 Infineon Technologies Ag Voltage supply arrangement for supplying electrical load e.g. mobile telephone, has voltage converter with input and output, and control circuit controlling two switches based on control signals, where one switch is coupled at output
CA2618349C (en) 2005-08-11 2016-05-31 Massachusetts Institute Of Technology Intravesical drug delivery device and method
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
US20100048503A1 (en) * 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
BRPI0820800B8 (en) 2007-12-11 2021-06-22 Massachusetts Inst Technology implantable medical device for controlled drug release
EP2599476A1 (en) 2008-04-04 2013-06-05 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
CN102176931B (en) 2008-08-09 2015-03-04 麻省理工学院 Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
ES2401007T3 (en) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Implantable drug delivery devices and manufacturing procedures thereof
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
ES2867399T3 (en) 2009-12-17 2021-10-20 Taris Biomedical Llc Implantable device with intravesical tolerability
WO2011089604A2 (en) 2010-01-20 2011-07-28 Theracoat Ltd Material and method for treating internal cavities
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
PT2600800T (en) 2010-08-05 2020-11-05 Taris Biomedical Llc Ureteral stent drug delivery device, kit, and method
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
CN103379902B (en) * 2011-02-04 2015-11-25 塔里斯生物医药公司 For the implantable device of the Co ntrolled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
SI2890384T1 (en) 2012-08-31 2022-02-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
AU2013318146B2 (en) 2012-09-18 2018-05-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
RU2666684C2 (en) 2013-03-15 2018-09-11 ТАРИС Биомедикал ЛЛК Device for drugs delivery with the drug permeable and the drugs delivery method
KR102339132B1 (en) 2013-03-15 2021-12-13 타리스 바이오메디컬 엘엘씨 Drug delivery devices and methods for drug delivery
JP6431528B2 (en) 2013-04-10 2018-11-28 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ Local drug delivery device and method for cancer treatment
CN113413393A (en) 2013-08-19 2021-09-21 塔里斯生物医药公司 Multi-unit drug delivery device and method
MX2016011333A (en) 2014-03-06 2016-12-07 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.

Also Published As

Publication number Publication date
KR102383496B1 (en) 2022-04-08
MX2015002452A (en) 2015-06-05
EP2890386A2 (en) 2015-07-08
CA2882575C (en) 2020-05-26
WO2014036556A3 (en) 2014-04-17
BR112015004110A2 (en) 2017-07-04
US10406335B2 (en) 2019-09-10
AU2013308465B2 (en) 2018-05-17
CN112516154A (en) 2021-03-19
RU2015109298A (en) 2016-10-20
KR20200120774A (en) 2020-10-21
IL237300B (en) 2020-02-27
RU2678308C2 (en) 2019-01-25
WO2014036556A2 (en) 2014-03-06
JP6309009B2 (en) 2018-04-11
US20170203085A1 (en) 2017-07-20
IN2015DN01560A (en) 2015-07-03
MX367070B (en) 2019-08-05
IL237300A0 (en) 2015-04-30
JP2015528469A (en) 2015-09-28
AU2013308465A1 (en) 2015-03-05
US9636488B2 (en) 2017-05-02
CN104812395A (en) 2015-07-29
KR20150043508A (en) 2015-04-22
CA2882575A1 (en) 2014-03-06
US20150165177A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
IL237300A0 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
IL239557A0 (en) Microarray for delivery of therapeutic agent and methods of use
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
HK1214628A1 (en) Dosing and administration of oligonucleotide cancer therapies
HK1201483A1 (en) Devices for targeted delivery of therapeutic implants
EP2887982A4 (en) Apparatus and methods for drug delivery using microneedles
SG11201500937UA (en) Extrusion methods and devices for drug delivery
EP2900150A4 (en) Plication lock delivery system and method of use thereof
EP2890440A4 (en) Devices and methods for the treatment of vascular disease
HK1211249A1 (en) Device and methods for targeted tissue drug delivery
SG10201604167XA (en) Blood treatment systems and methods
SG10201706578VA (en) Multiple drug infusion system and method
EP2651494A4 (en) Delivery catheter systems and methods
EP2720748A4 (en) Transdermal drug delivery system and method of using the same
EP2782631A4 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
IL237281A0 (en) Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
GB201319681D0 (en) System and method for drug delivery
IL230998A0 (en) Drug delivery system and method of manufacturing thereof
EP2755686A4 (en) Methods and systems for making microtablets for drug delivery
IL254182B (en) Drug delivery system and method of manufacturing thereof
EP2763716A4 (en) Solid drug delivery apparatus, formulations and methods of use
IL232390A0 (en) Device for pressure enhanced fractional treatment and drug delivery
EP2830552A4 (en) Ophthalmic drug delivery device and methods of use
HK1198470A1 (en) Drug delivery system and method of manufacturing thereof
EP2863981A4 (en) Catheter system for delivery of solutions